- Home
- IRIX
IRIX
IRIDEX Corporation
as 06-30-2025 3:31pm EST
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 16.5M | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 68.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $2.41 | Next Earning Date: | 08-07-2025 |
| Revenue: | $48,804,000 | Revenue Growth: | -2.24% |
| Revenue Growth (this year): | 9.61% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of IRIDEX Corporation (IRIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mercer Patrick | IRIX | President and CEO | Jun 13 '25 | Buy | $0.96 | 250 | $240.00 | 386,730 | |
| MOORE WILLIAM M | IRIX | Director | Jun 13 '25 | Buy | $0.97 | 20,000 | $19,372.00 | 188,650 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jun 11 '25 | Buy | $0.97 | 245 | $236.42 | 15,245 | |
| MOORE WILLIAM M | IRIX | Director | Jun 11 '25 | Buy | $0.97 | 30,000 | $29,121.00 | 188,650 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jun 9 '25 | Buy | $0.98 | 835 | $822.46 | 15,245 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jun 6 '25 | Buy | $0.97 | 1,500 | $1,455.00 | 15,245 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jun 2 '25 | Buy | $1.00 | 200 | $199.00 | 15,245 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | May 29 '25 | Buy | $0.99 | 200 | $197.00 | 15,245 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | May 28 '25 | Buy | $0.95 | 200 | $190.00 | 15,245 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | May 27 '25 | Buy | $1.00 | 100 | $100.00 | 15,245 |
Latest IRIDEX Corporation News
IRIX Breaking Stock News: Dive into IRIX Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 06/27/2025
Argus Research
5 days ago
Daily – Vickers Top Insider Picks for 06/26/2025
Argus Research
6 days ago
Daily – Vickers Top Insider Picks for 06/25/2025
GlobeNewswire
7 days ago
Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 06/24/2025
Argus Research
8 days ago
Daily – Vickers Top Insider Picks for 06/23/2025
Argus Research
11 days ago
Daily – Vickers Top Insider Picks for 06/20/2025
Argus Research
13 days ago
Daily – Vickers Top Insider Picks for 06/18/2025
Compare IRIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRIX IRIDEX Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.